Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Hello and welcome to Apotea Q4 presentation. We will have a short presentation on the numbers and events in the quarter, followed by a Q&A. Today's presenters are Pär Svärdson, CEO and co-founder, and I, Johan Mårild, CFO.
So, hello. We have had a good 2025 with stable growth and strong profitability. But if we look at the Q4 isolated, as we mentioned before, the profitability was a little bit weak. So please, you can show us the figures.
Yes. We had revenues in the quarter of 1,854,000,000 Swedish krona and a growth of 7%. We had a weak profitability in the quarter, an EBIT margin of 1.3%. As we go through the numbers, we will share more details on that in the presentation.
So, short quarterly update. During the quarter, we have started to shift focus from internal to external and launched a lot of growth initiatives. We have also successfully ramped up our facility in Varberg. And so now we are actually above 20,000 orders in just one day. And we also started to upgrade our e-commerce platform. And the reason for that is to be able to launch a lot of new sales-related initiatives like AI and so on on our platform. I look forward to that.
But yes, with the growth of 7% in the quarter, we now have rolling 12-month revenues of 7.2 billion Swedish kronor and an adjusted EBIT margin for 2025 of 4.2%. Let's take a closer look at the growth in the fourth quarter. The growth was of 7% in the quarter and was impacted by an internal focus during 2025, as mentioned. And that's related to launching the new fulfillment center in Varberg and also scaling up that, to the right you can see our gross margin development, and we had a lower gross margin in Q4 of 24.8%, and the gross margin was impacted by factors related to the fourth quarter, such as campaign sales and additional purchasing related costs. This was partly affected by the ramp-up in Varberg. And Q4 has always been an intense campaign period. With Black Friday, the intensity tends to increase year-over-year. This year, we had more campaign sales and also a lower campaign-related margin, and we had additional purchasing-related costs related to Varberg. An example of this is the calibration of purchases for our new logistics centers, which involves restocking products at a higher price from wholesalers and having products in stock that are later discounted, a situation often seen with some monthly specific assortments. Profitability was down in Q4 compared to a year ago. As mentioned, adjusted EBIT margin of 1.3%, and it was impacted not only by the lower gross margin, but also increased depreciation. To the right. You can see our Operating Cost and D&A in percentage of revenue. And as you can see, depreciation increased in percentage of sales by close to one percentage point in Q4. However, all other operating costs were down, and that was due to our ongoing efficiency work at Apotea related to logistics and elsewhere.
And if we look at 2025, we have had a transformative year. We started the year with all these AI initiatives that we continued through the year. We also launched a new hub in Årsta, south of Stockholm, and launched our Varberg facility in the third quarter, scaling it up during the fourth quarter. So it's been a lot of work this year with this internal focus.
Yes. Looking at the full year 2025, we had revenues of 7,203,000,000 Swedish kronor and an adjusted EBIT margin of 4.2%. The adjustments in 25 amounted to roughly 6 million krona in Q4, and in 24 we had 24 million of adjustments. These were related to the costs associated with the IPO in December 2024. We had good growth in 2025, with a 10.1% increase, and this growth, consistent with many previous years in Apotea's history, was driven by Rx, which grew by 13.4% last year due to strong underlying demand for buying prescription medicines online and our work to increase capacity in this area. We now employ more than 200 pharmacists. To the right, you can see our gross margin development, which was stable in 2025 compared to 2024. We had good profitability in 2025, with an adjusted EBIT margin of 4.2%. And that was well within our financial targets. And we did manage to have this good profitability despite additional costs related to the new fulfillment center in Varberg; to the right, you see our operating cost breakdown in percentage of revenue. And also looking at the full year, you can see that we managed to improve our efficiency. We had strong operating cash flow. However, specifically in Q4, we had a weaker cash flow, which was due to the payment of automation-related invoices for Varberg.
And the final payment as well.
The final payment. Q4 cash flow related to changes in working capital. As you can see to the right, we had significant investments in 2025, and the investments last year of 250 million were mainly related to the new fulfillment center in Varberg. We have now completed that investment, and going forward, we expect significantly lower investments. And these investments going forward will be related to our existing warehouses and our work to continue to improve our efficiency. As mentioned, Q4 cash flow was impacted by changes in net working capital. And as you can see, account payables declined in December compared to September. There are natural variations in the working capital, and they will fluctuate from time to time. Looking at the inventory turnover, we had an inventory turnover of 8.7 times, which is high but was affected by a slightly lower figure compared to a year ago, and was also due to the buildup of inventory in Varberg. We have a solid financial position and a high return on capital employed. Return on capital employed of 29.2% in 2025, somewhat down from a year ago. And that is due to the increased assets related to the new fulfillment center in Varberg. Looking on the right hand side of this slide, you can see that we have a net cash position as of December. And that is despite the significant investments in new capacity related to Varberg. So a solid financial position and a solid balance sheet.
And if we look at our focus ahead, we will continue to build the pharmacy of tomorrow, but shift the focus, as we said before, from internal to external and start a lot of new growth initiatives. And one example on that is that we have hired Joanna Hummel as a Chief Growth Officer, and she will work with our projects to work with our customer and improve our customer journey. And she will also work to launch a new site in Norway to sell our beauty and health assortment under the brand Apotea, and we will deliver these orders from our new facility in Varberg. So that will be very good, both for cost profile and for the customer. And we will also continue to scale up our Varberg facility and work more hours. So we will start working weekends and evenings quite soon.
Yes. As you can see in the report, the board of directors proposed a dividend to be resolved at the annual general meeting in May. Apotea has a long track record of share dividends, and the proposed dividend is based on the solid financial position of Apotea, despite significant investments. Yes. And with that, we are done with the presentation and open up for Q&A.
We have a solid financial position and a high return on capital employed.
The next question comes from Johan Fred from CIB. Please go ahead.
Good morning Pär and Johan, and thank you for taking my questions. A first one on the sales development throughout the quarter. More specifically from your earlier release, I interpreted as November had a slow start and that sales in December were weak. Still, you grew sales by 7%; should we interpret this as that? You saw a large inflow of orders in later November, assuming October was in line with expectations. And could you elaborate on sort of the sales development throughout the quarter, please?
And I can start to fill in. We can see from year to year. Black Friday is no longer just Black Friday. It's Black Week. And some e-commerce shops have more like Black month, and our customers are waiting until Black Week or something before they shop. That makes it harder to have a decent gross margin in November. And so people wait and shop during Black Friday, Black Week, and they don't shop in the beginning of December. So it's a little bit problematic in Q4, but it's isolated to Q4.
Was that the answer you wanted?
Yeah. Yeah. You received a disproportionate amount of orders in the middle to end of November, is that correct?
Yeah.
Yeah. Well, yeah. And as mentioned, we have had a higher campaign sales share in Q4.
And how much of this volume was shipped through from Nova versus Varberg during peak season in late November?
Most of it was sent from Nova due to very large orders and a smaller assortment in Varberg because of this fill-up. That made it cost a little bit higher because we couldn't really manage to send so many orders from Varberg because of the large number of SKUs in every order. Yeah.
Okay, cool. And sort of on the competitive environment in Q4, it was clearly intense. But do you think that the higher promotional activity was specifically related to the Black Week and Christmas period, or is it already reflecting a broader sort of consumer softness continuing into Q1 and 2026?
I think it's quite related to Q4.
The majority was sent from Nova due to very large order volumes and a smaller assortment in Varberg because of its ramp-up. Very clear. And finally, on the weaker gross margin, any chance that you can elaborate on the sort of margin declined by 2.2 percentage points, I believe? How much of this is related to lower product margins resulting from higher campaign pressure, and how much is, as you mentioned, related to higher fulfillment costs in Varberg? And also, of course, the additional procurement-related costs in Varberg, as you mentioned.
I would say that, of course, if you have a large assortment, there are 50,000 reasons for the gross margin. But the two main reasons are an increased share of campaign sales and a lower campaign margin. And the other is the restocking and the purchasing related costs. And out of those two, I would say that they are fairly even, these two factors. Then, of course, there are other factors as well, but these are the main factors, and mainly related to factors in the fourth quarter.
So those two are more prevalent than, say, higher fulfillment costs from you having to ship more volumes from Varberg. I believe that you previously said that this was impossible due to regulations.
Yeah. And I don't see that where we ship the items necessarily has an impact on the gross margin per se. We don't have any kind of.
It's more like tuning in. If you buy campaign items for one warehouse and then run out of stock, you have to repurchase them. So we have to work with optimization between the warehouses. And I think we failed a little bit on that.
Yes.
So, for example, if you're out of stock, you haven't done the purchasing properly or good enough. And it's, of course, more complex to do if you have two centers to fulfill rather than just one. So if you're kind of low on stock or out of stock, you may be forced to buy from wholesalers at a higher price. And then those have the kind of. Yes.
And I think we can call it a startup cost because it's not like a structural cost or something. It's more like you have to learn how to do it in a proper way.
Now, you mentioned that you're now starting to ship products to Norway from Varberg. I would say that, of course, if you have a large assortment, there are 50,000 reasons for the gross margin. A final one from me, then. Now, you mentioned that you're now starting to ship products to Norway from Varberg. I believe that you previously said that this was impossible due to regulations. What has changed there?
We are launching a beauty and health assortment, not the medicine assortment. So it's not a pharmacy. It's more health and beauty.
So our Norwegian subsidiary, Apotea, has a comprehensive pharmacy assortment in Norway. And in addition to this pharmacy assortment, they will also offer Apotea beauty and health products shipped from Varberg via Apotea to the Norwegian customer.
Okay, okay. So our Norwegian subsidiary, Apotea, will offer a comprehensive pharmacy assortment in Norway. So essentially, you're starting a new subsidiary that handles the beauty and health category. So Apotea's Norwegian subsidiary will offer a comprehensive pharmacy assortment in Norway. So our Norwegian subsidiary, Apomera, will offer a comprehensive pharmacy assortment in Norway. Those were all my questions for now. Thank you so much for taking the time.
Our Norwegian subsidiary, Apomera AB, has a comprehensive pharmacy assortment in Norway.
The next question comes from Victor Hansen from DNB Carnegie. So our Norwegian subsidiary, Apotea, has a comprehensive pharmacy assortment in Norway.
Hi. Thanks for taking my questions. I guess a bit of a follow-up on some of the previous questions here. Starting with competition, since they've been very tough in Q4, from what we can read in the market. You mentioned that this impacted your gross margins. And you also mentioned and you spoke about it here as well, that the gross margin effects are to a large extent isolated to Q4, as you say. But we know that several pharmacy and beauty competitors have recently built new, highly automated fulfillment capacity. So why should the tough competition be isolated to Q4?
I think we will see strong competition going forward. Well, going forward as well. And I think it's good for us because we love competition, and I think we will be stronger and more profitable and grow faster with strong competition because it helps us as a company.
And we always want to have attractive prices, but we don't feel an increased pressure to lower our prices even more or to change that dynamic.
Yeah, I mean, it's like one week. So you expect less price pressure in Q1 than in Q4.
Yeah, I mean, it's like a week. I mean, everyone has campaigns at the same time, with very high discounts. So, is it more about that rather than a competition problem?
Yeah.
Okay. And the second, the second part of your gross margin weakness. You mentioned the additional procurement-related costs in Varberg. Could you elaborate a bit more on what this means? More precisely. And if you could quantify it.
And then, if you look at buying and filling up the warehouse, for example, for Rx, you have different prices in different months. And the prices go up and down. And if you buy them in the wrong month, they are much more expensive. So that one example. Another example, if you buy for a campaign and we ship 50% to Varberg, 50% to Monongahela, and we don't deliver 50/50, we need to resupply them, maybe at a higher price. So, if we don't have stock in Årsta and we need to ship it from Årsta, then we can't sell it. And then we sell something else with a lower margin. So it's a lot of cost like that. And I think it's more, as I said before, a startup problem because we learn every day and do it better and better, and this effect goes down.
Makes sense. And that ties into my third question. So, regarding the inventory levels in Varberg, you previously complained about them in Q3 as well. So are you satisfied now with inventory levels in Varberg? We're still working to fill it. So can you now deliver L and XL orders from Varberg?
I think we will probably never be satisfied with the stock level. But we are. We have absolutely done a lot of work since Q4, and we will continue to improve the assortment over time. And we are like tuning it every day a little bit. So we are absolutely working on it.
But can you deliver XL orders from Varberg now, or is that something for the future still?
We deliver a lot of extra large orders from Varberg, but we want to deliver even more. And that's why we are now starting to work more hours. So, very soon, we will start working on weekends and evenings in Varberg, and that will help us deliver much more orders from Varberg. And that will help us. We deliver a lot of extra large orders from Varberg, but we want to deliver even more.
And part of the scale-up includes, in addition to launching more shifts in Varberg, adding shipping methods, and continuing to calibrate the assortment. So, enabling a higher share of orders to be fulfilled there.
And part of the scale-up, in addition to launching more shifts in Varberg, adding shipping methods, and also continuing to calibrate the assortment. On Rx, our sales growth slowed to 8%, slower than in previous quarters, despite during the quarter increasing the number of pharmacists significantly. You mentioned more than 200 now employed. So what caused this growth slowdown? Were there a lack of orders or is your setup in Varberg not fully operational yet, or what's the reason behind that?
They have now started to work full-time. But it's still a lot of small, related startup problems. We need to be really sure that every order is correct, so we need to check everything much more thoroughly. It takes some time to scale up.
Yeah.
And also, you had a very strong growth in the previous quarter related to the changes in high cost coverage. That could also have had some impact in the quarter.
But we see a strong demand for Rx. We deliver a lot of extra large orders from Varberg, but we want to deliver even more.
So I will continue to increase our capacity this year.
So quite soon, we will start working on weekends and evenings in Varberg, and that will help us to deliver many more orders from Varberg. Could you give any timing schedule for when Rx is more operational in Varberg?
I think it's a little bit better today compared to yesterday. So we scale up every day a little bit. And so I think it's a continuous process.
We deliver a lot of extra large orders from Varberg, but we want to deliver even more. We deliver a lot of extra-large orders from Varberg, but we want to deliver even more. Final question from me is the ESG regulation. Investors are still following this quite closely. So I'm wondering if you could give us an update on the implications for you from this during Q4 and if you have any thoughts on it ahead. Are you seeing any changes in consumer behavior?
No. Not really. I mean, it affects us just a little bit. And if we look at our figures, that's not the reason for the profitability in Q4. So, it's a small effect as we mentioned before, but it's very small. So I think it's very bad for our customer and I don't like it, but for Apotea it's not a big problem. So it's more for people in rural areas or old people and so on.
It's annoying as a customer. And.
And people really don't like it, but that's another story. But it's not a big problem for us, but it's a problem for people in these rural areas.
Yeah.
The next question comes from Daniel Schmidt from Danske Bank. No.
Yes. Good morning, Pär and Johan. Maybe a follow up from me. We talked a lot about Q4 and what happened, but from more from a top line perspective. Pär, you already mentioned three months ago that you shifted your focus from internal to external, implying that top line growth would pick up. So, what really went wrong in Q4? You know that it is a campaign intensive period, and that has been sort of the trend for many years now. So what do you think went wrong?
Do you mean with the top line or with the profitability?
With the growth ambitions? Basically, because you also said in Q3 that now's the time to shift focus.
Yeah. And this shift takes time. We have started a lot of initiatives, such as preparing for the site in Norway for Joanna Hummel, rebuilding our e-commerce platform, and launching AI initiatives. But I think it will take us a few quarters, or this year we will see a change, but you can't really change customer behaviors, a lot of technology, and so on. In just a few weeks, we need some time.
We have started many initiatives, including preparing for the site in Norway for Joanna Hummel, rebuilding our e-commerce platform, and launching AI initiatives. Does that mean that you think that growth will be below your target for a couple of quarters?
We have no forecast for that, but we still think we will see a significant change. Give us some time, as it takes time, but we will absolutely focus on it.
We have started many initiatives, such as preparing for the site in Norway for Joanna Hummel, rebuilding our e-commerce platform, AI initiatives, and so on. And I completely understand that Q4 has become very concentrated to a couple of weeks. And that makes it more difficult, I guess, to find your place in the market, maybe, but given that that's been a trend for now, a number of years and it's become more and more concentrated, is there any reason to believe that that behavior would change in any way? Going. Looking ahead.
I think this Black Week. Black Week will continue to be problematic for the retail in the coming years as well. We need to work to mitigate its problems, but the phenomenon is out there, and it will persist in 2026 as well. So, I think we need to just adapt it and behave and try to.
And the initiatives that we are working on are focusing on improving our customer offering even further. And it takes time, but it will also have an impact not only when you sell at the normal price but also in campaign periods. The growth engine of Apotea has always been to have satisfied and returning customers, who over time purchase more and more from Apotea.
And I think a lot of these initiatives we have been doing during the autumn have been very, very good for Apotea. We have a weak profitability, but we have also scaled up the Varberg facility and solved a lot of issues with it. And so we are really well prepared with that facility for the coming years. And so I think we had a weak profitability, but also a lot of good initiatives. And we will continue to work with them.
Yeah.
A year.
Ago.
The Varberg facility was launched this summer, and in Q3, we reported that we had 10,000 orders a day fulfilled in Varberg. And now we have a record of roughly 21,000 orders. So, it's a very successful ramp-up.
Yeah. No, but I think you're absolutely doing what you can. I just fear that Q4 has become a quarter that's flooded with products and campaigns, and that doesn't seem to go away. So it's more and more signified by very hard competition, low growth, and very low profitability. And it's hard to change that. And I guess you try to do what you can and we'll see what happens next year.
Yeah. Yeah, you're probably correct. But if you know something, you can work with it. And you can also be best in class and you can own it. It's a threat but also a possibility. So, if you work with it, you can earn a lot from it as well.
Yeah. Yeah. I'm just saying you knew that already this time. And that didn't help. But maybe you're going to be more prepared next year.
We hope so.
Yeah. I think the fourth quarter has been very focused on Black Week.
Yeah.
The next question comes from Benjamin Wahlstedt from ABG Sundal Collier. I think the fourth quarter and the last year have been very focused on Black Week.
Good morning. So, a bit of a follow-up to start. You mentioned a negative impact from campaigns. Obviously, you've also been very clear in all communication with the market and your customers that you are price leaders. And you've also been campaign driven throughout your history as a company. And I was wondering, is there any specific competitors that are making you push this price leading position even further in the quarter or what changed?
The fourth quarter or the last year has been very focused on Black Week. But I think it's more driven from a customer side that they wait. They don't shop in the beginning of November and in the beginning of December, because they focus more and more on Black Week. So it's more customer-driven than competitor-driven.
All right. Thank you. A bit of a detailed related question as well. Are you using Google automated discounts?
No.
No. But I think it's more driven by customers who wait. You also talked about working evenings and weekends in Varberg. I will assume this is done in tandem with added scale. Or should we expect lower scale and opex near term?
Sorry, I didn't really get to my question.
You mentioned adding evening and weekend shifts in Varberg in this presentation. When will this happen? Should we expect any sort of near-term higher costs related to this, or how should we interpret this?
And then we try to balance it between our model and Varberg. And we want to deliver more orders from Varberg, because then we can handle the growth in Varberg. And we can also start delivering to Norway from Varberg. And then we need more hours. So, I think it has both positive and negative effects on our costs.
All right. Thank you. I might have missed this. You spoke about your inventory position previously as well. I know that your inventory level is down quarter over quarter. This is not seen in previous years. And this in a time where you say you're building inventories in Varberg. How should we understand this?
Inventory stock goes a little bit up and down. And it varies between different quarters. It's like one day you measure it. So it goes up and down. But over time, I think two warehouses will make this stock a little bit bigger, but with better AI support and so on. You can lower the stock and still be able to deliver. So I think we can have a quite stable stock level going forward. But, of course, two warehouses drive a little bit more stock.
Yeah, absolutely. Perhaps a sort of modeling related question. What should we expect in terms of maintenance CapEx now that you're done with Varberg?
We have very little maintenance CapEx. But the CapEx that we have had historically, which has not been related to building new capacity, has been in the range of 50 to 70 SEKm. And we expect that pattern to continue. And the investments will be related to improved efficiency, focusing more on efficiency rather than building new capacity.
Like building new workstations for picking and so on.
But the CapEx solely for changing spare parts is very, very little.
And this in a time where you say you're building inventories in Varberg. So 50 to 70 per annum going forward.
Yeah something.
That.
Good. But over time, I think two warehouses will make this stock a little bit bigger, but with better AI support and so on. That's all I had today.
And this in a time where you say you're building inventories in Varberg.
Okay, I think that was the final question. Thank you for taking the time. And listen to us, and we wish you a good day.
Thank you very much.
Bye.



















